- Home
- CRNX
as 08-27-2025 4:00pm EST
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.8B | IPO Year: | 2018 |
| Target Price: | $74.33 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.10 - $62.53 | Next Earning Date: | 08-07-2025 |
| Revenue: | $1,392,000 | Revenue Growth: | 0.51% |
| Revenue Growth (this year): | 489.51% | Revenue Growth (next year): | 661.93% |
Stock Insider Trading Activity of Crinetics Pharmaceuticals Inc. (CRNX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Aug 22 '25 | Sell | $30.43 | 30,000 | $912,900.00 | 66,270 | |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Aug 20 '25 | Sell | $29.18 | 6,492 | $189,436.56 | 66,270 | |
| Betz Stephen F. | CRNX | Chief Scientific Officer | Jun 12 '25 | Sell | $32.23 | 97,483 | $3,141,877.09 | 99,713 |
Latest Crinetics Pharmaceuticals Inc. News
CRNX Breaking Stock News: Dive into CRNX Ticker-Specific Updates for Smart Investing
MT Newswires
2 months ago
Crinetics Pharmaceuticals Insider Sold Shares Worth $3,141,877, According to a Recent SEC Filing
GlobeNewswire
2 months ago
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
GlobeNewswire
3 months ago
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
3 months ago
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
Simply Wall St.
3 months ago
Is There An Opportunity With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) 20% Undervaluation?
GlobeNewswire
3 months ago
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
GlobeNewswire
4 months ago
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GuruFocus.com
4 months ago
Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and ...
Compare CRNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRNX Crinetics Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.